Safety of Sodium Glucose Co- Transporter 2 Inhibitors based on ADR’S and FBS, PPBS & HBA1C Parameters in Type-2 Diabetes Mellitus

Abstract

When compared to the several medications accessible to the doctor to treat type 2 diabetes, sodium-glucose cotransporter-2 (SGLT2) inhibitors offer a distinct therapeutic activity. Due to its insulin independent effect, SGLT2 inhibitors have been proven to have a comparatively low risk of hypoglycaemia. When taken as monotherapy or in conjunction with other oral hypoglycaemic medications or insulin treatment, SGLT2 inhibitors are well tolerated and have been used safely. Patients with ADR’s After Using Canagliflozin where Hypotension (29%) was more common ADR followed by Dehydration (26%), Weight loss (15%), Polyuria (12%), Vaginal Candidiasis (7%), UTI (3%), Hypoglycaemia (5%) and Ketoacidosis (3%). Percentage of Patients with ADR’s After Using Canagliflozin in which hypotension had highest percentage (25%) of occurrence in Canagliflozin prescribed patients. Patients with ADR’s After Using Dapagliflozin where Dehydration (26%) was more common ADR followed by Hypotension (23%), Weight loss (19%), Polyuria (12%), Vaginal Candidiasis (9%), UTI (4%), Hypoglycaemia (5%) and Ketoacidosis (2%). Percentage of Patients with ADR’s After Using Dapagliflozin in which dehydration had highest percentage(14.69%) of occurrence in Dapagliflozin prescribed patients. Patients presented with more than one ADR in which dehydration along with hypotension was more common when compared to others in both Canagliflozin and Dapagliflozin prescribed patients.

Patients with ADR’s After Using Canagliflozin versus Dapagliflozin in which hypotension was more common ADR after using Canagliflozin whereas Dehydration was more common ADR after using Dapagliflozin. Mean FBS and PPBS of Control, Canagliflozin and Dapagliflozin were similar, hence safety was similar for Control and Canagliflozin as well as it is similar for Control and Dapagliflozin. From this study, we concluded that Patients with ADR’s After Using Canagliflozin versus Dapagliflozin in which hypotension was more common ADR after using Canagliflozin whereas Dehydration was more common ADR after using Dapagliflozin. ADRs in Control group in which weight gain was negative effect and Hypoglycaemia was found to be more in Control group compared to Canagliflozin and Dapagliflozin prescribed groups whereas weight loss was positive effect in Canagliflozin and Dapagliflozin prescribed groups. In accordance with hypoglycaemia as an ADR it is more in Control group than in Canagliflozin and Dapagliflozin groups. This shows that there was slight difference but similar Safety by using Canagliflozin versus Dapagliflozin